Tevogen Bio reports positive trial results for T-cell therapy targeting COVID-19
Summary: Tevogen Bio has published positive results from its phase I trial of TVGN 489, a T-cell therapy targeting SARS-CoV-2. The study involved 30 patients, with those receiving the therapy showing faster symptom improvement and higher viral elimination rates compared to a control group.
The trial included high-risk patients, many of whom were immunocompromised. Notably, the therapy was well-tolerated, and no cases of disease progression or Long COVID were reported in the treatment group. The persistence of the T-cells in patients for six months was an unexpected finding.
Tevogen aims to mainstream cell therapy with its off-the-shelf T-cell products, which are designed for immediate use. The company believes its technology could address significant unmet medical needs in infectious diseases and cancers.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings